PMID- 35901016
OWN - NLM
STAT- MEDLINE
DCOM- 20220801
LR  - 20220815
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 7
DP  - 2022
TI  - Metformin and thyroid carcinoma incidence and prognosis: A systematic review and 
      meta-analysis.
PG  - e0271038
LID - 10.1371/journal.pone.0271038 [doi]
LID - e0271038
AB  - Metformin has been suggested to reduce thyroid cancer incidence and to improve 
      thyroid cancer prognosis. We aimed to evaluate the associations between metformin 
      and thyroid cancer incidence and prognosis 
      (metastasis/recurrence/progression-free survival). Cochrane Library, PubMed, 
      ClinicalTrials.gov, and U.S. National Library of Medicine Clinical Trials were 
      searched through the end of December 2021. Data were collected from original 
      observational studies or clinical trials on the incidence or prognosis of thyroid 
      carcinoma outcomes in type 2 diabetes mellitus (T2DM) patients with and without 
      metformin use. Risk of bias in non-randomized studies of interventions (ROBINS-I) 
      tool and Grading of Recommendations, and Assessment, Development and Evaluations 
      (GRADE) approach were used to evaluate the risk of bias and quality of the body 
      of evidence, respectively. In general, 4 studies were related to the thyroid 
      cancer incidence, including 1,705,123 participants metformin users and non-users 
      and yielding a total of 3,238 thyroid cancer events; 3 studies reported the 
      prognosis of thyroid carcinoma based on a total of 4,972 individuals with primary 
      thyroid carcinoma and comorbid type 2 diabetes, and the number of thyroid cancer 
      prognosis cases ranged from 3 to 79. The overall risk of bias of the included 
      studies ranged from moderate to serious. In the random-effects model, the summary 
      relative risk (SRR) for thyroid cancer incidence was 0.743 (95% CI: 0.453-1.220; 
      I2 = 88.7%, low certainty) comparing metformin users to non-users; and SRR for 
      the prognosis of thyroid cancer was 0.504 (95% CI: 0.178-1.430; I2 = 57.5%, low 
      certainty). Non-statistically significant negative associations between metformin 
      use and incidence and prognosis of thyroid cancer were found in the current 
      analysis, although the quantity and quality of the evidence were limited. Futher 
      investigation is needed to evaluate the clinical benefits of metformin on thyroid 
      cancer prevention and treatments.
FAU - Wang, Zikun
AU  - Wang Z
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Indiana 
      University Bloomington, Bloomington, Indiana, United States of America.
FAU - Luo, Juhua
AU  - Luo J
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Indiana 
      University Bloomington, Bloomington, Indiana, United States of America.
FAU - Zhang, Yijia
AU  - Zhang Y
AD  - Department of Obstetrics and Gynecology and Department of Epidemiology, Columbia 
      University Irving Medical Center, New York, New York, United States of America.
FAU - Xun, Pengcheng
AU  - Xun P
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Indiana 
      University Bloomington, Bloomington, Indiana, United States of America.
FAU - Chen, Zhongxue
AU  - Chen Z
AUID- ORCID: 0000-0003-2537-7843
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Indiana 
      University Bloomington, Bloomington, Indiana, United States of America.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220728
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Incidence
MH  - *Metformin/therapeutic use
MH  - *Thyroid Neoplasms/drug therapy/epidemiology
PMC - PMC9333305
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/07/29 06:00
MHDA- 2022/08/02 06:00
PMCR- 2022/07/28
CRDT- 2022/07/28 13:42
PHST- 2022/02/28 00:00 [received]
PHST- 2022/06/22 00:00 [accepted]
PHST- 2022/07/28 13:42 [entrez]
PHST- 2022/07/29 06:00 [pubmed]
PHST- 2022/08/02 06:00 [medline]
PHST- 2022/07/28 00:00 [pmc-release]
AID - PONE-D-22-05667 [pii]
AID - 10.1371/journal.pone.0271038 [doi]
PST - epublish
SO  - PLoS One. 2022 Jul 28;17(7):e0271038. doi: 10.1371/journal.pone.0271038. 
      eCollection 2022.